News and Announcements
Leaf Resources Annual Update 2016; Collaboration with Novozymes, Multiple MOU and Project Agreements & Over $4m in Placements
- Published January 16, 2017 4:53PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
In today’s society consumers needs are shaping for demand of “greener and more natural products”, which can been seen throughout almost every industry. Leaf Resources Limited, does exactly what society is demanding… focusing on the production of making sustainable products from plant biomass. The commercialisation of Leaf’s proprietary, the GlycellTM process was significantly enhanced throughout 2016 with the following advancements :
- Leaf Resources collaborated with Novozymes, the world’s largest producer of enzymes.
- Started 5 project agreements with Claeris LLC of Texas, a world-class renewable project developer.
- MOU with agencies of the Malaysian federal government to advance the development of the GlycellTM process facility in Malaysia.
- Leaf Resources during 2016, were named #4 in “Hottest Emerging Company” in the Bioeconomy in November, San Francisco.
- Finally, raising over $4 million in placements.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
